0 avis
Immune checkpoint inhibitor-associated myocarditis and coronary artery disease: There may be more than meets the eye!
Archive ouverte
International audience. The Immune checkpoint blockers (ICB) have greatly improved clinical outcomes in multiple cancer types and are increasingly being used in earlier disease settings alone or in combination with other therapies. However, rare but life-threatening complications defined as immune-related adverse events (irAE) as ICI-induced myocarditis can occur, justifying close monitoring and specific management